CA1116597A - 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones - Google Patents
1,2,3,5-tetrahydroimidazothienopyrimidin-2-onesInfo
- Publication number
- CA1116597A CA1116597A CA000333380A CA333380A CA1116597A CA 1116597 A CA1116597 A CA 1116597A CA 000333380 A CA000333380 A CA 000333380A CA 333380 A CA333380 A CA 333380A CA 1116597 A CA1116597 A CA 1116597A
- Authority
- CA
- Canada
- Prior art keywords
- alkyl group
- carbon atoms
- formula
- hydrogen atom
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 24
- 239000002253 acid Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 12
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 53
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 abstract description 6
- 230000002744 anti-aggregatory effect Effects 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 2
- 229960004676 antithrombotic agent Drugs 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- -1 i~e. Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- LDXCWOSUWRNYEW-UHFFFAOYSA-N 2,4-dichloro-5,6-dimethylthieno[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C(C)=C(C)SC2=N1 LDXCWOSUWRNYEW-UHFFFAOYSA-N 0.000 description 2
- PNLDBSNRSSNUAA-UHFFFAOYSA-N 2-chloro-5,6-dimethyl-1,4-dihydrothieno[2,3-d]pyrimidine Chemical compound N1=C(Cl)NCC2=C1SC(C)=C2C PNLDBSNRSSNUAA-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- FVACZQHQBKPPMX-UHFFFAOYSA-N quinazolin-2-one Chemical compound C1=C[CH]C2=NC(=O)N=CC2=C1 FVACZQHQBKPPMX-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AQECFYPZMBRCIA-UHFFFAOYSA-N 2,4-dichlorothieno[3,2-d]pyrimidine Chemical class ClC1=NC(Cl)=C2SC=CC2=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- YLVVAWCDANPADI-UHFFFAOYSA-N 5,10-dihydro-3h-imidazo[2,1-b]quinazolin-2-one Chemical class C1C2=CC=CC=C2N=C2N1CC(=O)N2 YLVVAWCDANPADI-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005227 alkyl sulfonate group Chemical group 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- HHCUNJGQXLQWKL-UHFFFAOYSA-N chembl1189223 Chemical compound N1=C2NC(=O)CN2CC2=C1SC(C)=C2C HHCUNJGQXLQWKL-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- OTSAXGGQQPWCFB-UHFFFAOYSA-N imidazo[2,1-b]quinazoline Chemical class C1=CC=CC2=NC3=NC=CN3C=C21 OTSAXGGQQPWCFB-UHFFFAOYSA-N 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP97832/78 | 1978-08-11 | ||
| JP9783278A JPS5527105A (en) | 1978-08-11 | 1978-08-11 | Imidazothienopyrimidinones compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1116597A true CA1116597A (en) | 1982-01-19 |
Family
ID=14202683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000333380A Expired CA1116597A (en) | 1978-08-11 | 1979-08-08 | 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4284773A (enFirst) |
| EP (1) | EP0008408B1 (enFirst) |
| JP (1) | JPS5527105A (enFirst) |
| AU (1) | AU529068B2 (enFirst) |
| CA (1) | CA1116597A (enFirst) |
| CS (1) | CS219256B2 (enFirst) |
| DE (1) | DE2961552D1 (enFirst) |
| DK (1) | DK153844C (enFirst) |
| ES (1) | ES483289A1 (enFirst) |
| GR (1) | GR73839B (enFirst) |
| IL (1) | IL57923A (enFirst) |
| MX (1) | MX6242E (enFirst) |
| PH (1) | PH15530A (enFirst) |
| SU (1) | SU880252A3 (enFirst) |
| YU (1) | YU41170B (enFirst) |
| ZA (1) | ZA793909B (enFirst) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287340A (en) * | 1979-08-27 | 1981-09-01 | Warner-Lambert Company | Dihydro-oxo-pyrido[1,2-a]thienopyrimidine compounds |
| ZW11781A1 (en) * | 1980-06-27 | 1982-01-20 | Hoffmann La Roche | Pyrimidine derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| GB0808950D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| CA2920856C (en) | 2013-08-09 | 2026-03-03 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3890321A (en) * | 1971-09-20 | 1975-06-17 | Pfizer | 6-aryl-5-ethyl-pyrimidin-4-ol compounds useful as intermediates and bronchodilators |
| US3932407A (en) * | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
| DE2411273A1 (de) * | 1974-03-06 | 1975-09-18 | Schering Ag | Neue thieno eckige klammer auf 2,3-d eckige klammer zu pyrimidinone und verfahren zu ihrer herstellung |
-
1978
- 1978-08-11 JP JP9783278A patent/JPS5527105A/ja active Granted
-
1979
- 1979-07-30 IL IL57923A patent/IL57923A/xx unknown
- 1979-07-31 ZA ZA00793909A patent/ZA793909B/xx unknown
- 1979-08-03 PH PH22860A patent/PH15530A/en unknown
- 1979-08-03 CS CS795377A patent/CS219256B2/cs unknown
- 1979-08-08 EP EP79102869A patent/EP0008408B1/en not_active Expired
- 1979-08-08 DE DE7979102869T patent/DE2961552D1/de not_active Expired
- 1979-08-08 CA CA000333380A patent/CA1116597A/en not_active Expired
- 1979-08-09 ES ES483289A patent/ES483289A1/es not_active Expired
- 1979-08-09 AU AU49735/79A patent/AU529068B2/en not_active Ceased
- 1979-08-09 GR GR59809A patent/GR73839B/el unknown
- 1979-08-10 DK DK336779A patent/DK153844C/da not_active IP Right Cessation
- 1979-08-10 SU SU792798503A patent/SU880252A3/ru active
- 1979-08-10 MX MX798313U patent/MX6242E/es unknown
- 1979-08-10 YU YU1947/79A patent/YU41170B/xx unknown
- 1979-08-13 US US06/066,113 patent/US4284773A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE2961552D1 (en) | 1982-02-04 |
| MX6242E (es) | 1985-01-28 |
| JPS5527105A (en) | 1980-02-27 |
| IL57923A0 (en) | 1979-11-30 |
| DK153844C (da) | 1989-01-30 |
| JPS627914B2 (enFirst) | 1987-02-19 |
| AU4973579A (en) | 1980-02-14 |
| US4284773A (en) | 1981-08-18 |
| YU194779A (en) | 1983-10-31 |
| PH15530A (en) | 1983-02-09 |
| GR73839B (enFirst) | 1984-05-04 |
| CS219256B2 (en) | 1983-03-25 |
| SU880252A3 (ru) | 1981-11-07 |
| EP0008408A1 (en) | 1980-03-05 |
| EP0008408B1 (en) | 1981-12-09 |
| DK153844B (da) | 1988-09-12 |
| IL57923A (en) | 1982-09-30 |
| YU41170B (en) | 1986-12-31 |
| ES483289A1 (es) | 1980-09-01 |
| ZA793909B (en) | 1980-10-29 |
| DK336779A (da) | 1980-02-12 |
| AU529068B2 (en) | 1983-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0008408B1 (en) | 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions | |
| CA1134362A (en) | Benzimidazoles, their preparation and their use as pharmaceutical compositions | |
| PL190174B1 (pl) | Nowe związki, tienopirymidyny, sposób ich wytwarzania oraz preparat farmaceutyczny | |
| US3888851A (en) | 2,4-diamino-substituted thieno(3,2-d)pyrimidines and salts thereof | |
| PL136217B1 (en) | Method of obtaining novel derivatives of 4-amino-6,7-dimetoxy-2-piprazinoquinazoline | |
| YU45860B (sh) | Postupak za dobijanje tetracikličnih imidazodiazepina | |
| GB2069481B (en) | Substituted imidazole derivatives | |
| US4610987A (en) | Imidazoquinazolin-2-one compounds | |
| CA1055024A (en) | Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo (2,1-b)quinazolin-2-ones | |
| IT9019884A1 (it) | Derivati di tieno-triazolo-diazepine, un procedimento per la loro preparazione e composizioni terapeutiche che li contengono | |
| KR910003153B1 (ko) | 7-피페리디노-1,2,3,5-테트라하이드로이미다조[2,1-b]퀴나졸린-2-온의 제조방법 | |
| JPS5724369A (en) | Pyrimidine derivative and its preparation | |
| DE2200764A1 (de) | Neue thieno eckige klammer aff 2,3-d eckige klammer zu pyrimidine und verfahren zu ihrer herstellung | |
| JPS646261A (en) | 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component | |
| AU609547B2 (en) | Acyl derivatives of hydroxy pyrimidines | |
| ES8306733A1 (es) | Derivados de anilina y sus sales. | |
| GB2169291A (en) | 8a-acylaminoergolines, their production and pharmaceutical compositions containing them | |
| GB2171995A (en) | Pharmaceutically active 8-heteroarylthio-5, 6, 7, 8-tetrahydroquinolines | |
| ES8604220A1 (es) | Un procedimiento para preparar derivados de pirimidoisoqui- nolina | |
| US4552956A (en) | Partially hydrogenated pyrazolo, pyrimido and thiazolo[1,4]benzoxazines | |
| KR100316354B1 (ko) | A-2수용체친화성을갖는2-치환된아데노신 | |
| KR840001316B1 (ko) | 이미다조티에노피리미디논 유도체의 제조방법 | |
| EP0001401A1 (en) | Thienobenzazepine derivatives, processes for their production and pharmaceutical compositions containing them | |
| PH19310A (en) | 1,2-fused 1,4-benzodiazepine compounds,process for their preparation and compositions containing them | |
| EP0195374A3 (en) | N-substituted 3,4-dihydropyrimidine derivatives, process for the production thereof and composition containing same for treating disorders of cardiovascular system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |